Liver cancer
Conditions
Interventions
Case series:Taking apatinib mesylate tablets orally once a day, initial dose 250mg, 28 days is one medication cycle. The treatment ends when the patient develop cancer recurrence/metastasis or death.
Sponsors
Chinese People's Liberation Army (PLA) General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged=18years male and female; 2. Patients with hepatocellular carcinoma who have undergone surgical resection or local ablation(PEI or percutaneous puncture or intraoperative RFA); 3. Postoperative pathology suggested no residual lesion at the cutting edge; 4. Preoperative radiology (CT, MRI, PET-CT etc), intraoperative or postoperative pathology examination revealed one risk factor for recurrence at least: Group1: Tumor number =3; Group2: The differentiation level is III or IV. (Edmondson-Steiner Four-stage (I-IV) classification method ); Group3: The tumor thrombus of the hepatic vein, portal vein, bile duct or inferior vena cava should be visible to the naked eye or under the microscope and can be surgically removed, except for single tumor which diameter less than 2cm; Group4: AFP Elevated before surgery (=200ng/ml), and AFP =200ng/ml 1~2 months after surgery; Group5: Tumor rupture; Group6: There was no definite fibrous capsule or incomplete capsule between tumor and liver tissue; Group7: Satellite nodules are seen in the resection specimen; Group8: Special location tumor (For example: adjacent to the left, middle, right or inferior vena cava of the liver ). 5. Voluntarily join this study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Allergy to apatinib mesylate tablets and/or its excipients has been confirmed; 2. Pregnant or lactating women; 3. Apatinib contraindication; 4. The doctor considered the inclusion inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival;Time to recurrence; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;1 year recurrence rate, 2 year recurrence rate, 3 year recurrence rate;Life quality score (EORTC QLQ-C30 V3.0 or HCC-18); | — |
Countries
China
Contacts
Public ContactRong Liu
Chinese People's Liberation Army (PLA) General Hospital
Outcome results
None listed